<DOC>
	<DOCNO>NCT01085084</DOCNO>
	<brief_summary>The study aim evaluate safety clinical effect daily oral treatment laquinimod capsule ( 0.5mg /day 1mg /day ) active lupus arthritis patient . Laquinimod novel immunomodulating drug currently advance stage development Teva Pharmaceuticals Ltd. For Multiple Sclerosis .</brief_summary>
	<brief_title>Laquinimod Study Systemic Lupus Erythematosus ( SLE ) Patients With Active Lupus Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>1 . Subjects diagnose SLE . 2 . Subjects active lupus arthritis evident At least 4 tender 4 swollen joint Active synovitis â‰¥ 1 joint loss functional range movement 1 . Subjects severe renal impairment dialysis 2 . Severe , unstable and/or progressive CNS lupus 3 . Subjects clinically significant unstable medical surgical condition 4 . Women pregnant nursing intend study period . 5 . Women childbearing potential practice acceptable method birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Systemic Lupus Erythematosus ( SLE )</keyword>
	<keyword>Lupus Arthritis</keyword>
	<keyword>Laquinimod</keyword>
</DOC>